Search

Displaying results 91 - 100 of 759 in total
  1. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.

  2. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54858] In the Phase 3 FIBRONEER-ILD trial, nerandomilast led to a smaller decline in forced vital capacity (FVC) than placebo over 52 weeks. [A274591]

  3. Drug

    Ginkgo biloba

    go.drugbank.com/drugs/DB01381
    ApprovedInvestigationalNutraceutical

    _Ginkgo biloba_ is found in a number of homeopathic and over-the-counter herbal products and dietary supplements, but it has no approved therapeutic indications by regulatory bodies, such as the FDA, EMA

  4. Drug

    Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen

    go.drugbank.com/drugs/DB16709
    Approved

    The product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting.

  5. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    ApprovedInvestigational

    [A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937]

  6. Drug

    Phenolphthalein

    go.drugbank.com/drugs/DB04824
    ApprovedWithdrawn

    Phenolphthalein was withdrawn in Canada due to concerns with carcinogenicity in 1997.

  7. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.

  8. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneum...

  9. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    [A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin … [L38919] On January 19, 2022, the European Commission approved avacopan for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA) - the

  10. Drug

    Abaloparatide

    go.drugbank.com/drugs/DB05084
    ApprovedInvestigational

    [L740] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe [L43552] and the drug was fully authorized … by the European Commission on December 19, 2022.